Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy by Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani, Hanna Sanoff, Reza Hadi, Esmat Samiei, Alan P. Venook, Mark J. Ratain, Naim Rashid, Benjamin G. Vincent, Xueping Qu, Yujia Wen, Michael Kosorok, William F. Symmans, John Paul Y. C. Shen, Michael S. Lee, Scott Kopetz, Andrew B. Nixon, Monica M. Bertagnolli, Charles M. Perou, Federico Innocenti

“…The patients were enrolled in a randomized clinical trial receiving either cetuximab or bevacizumab in combination with chemotherapy. An external cohort of paired CRC normal and tumor samples, along with protein-protein interaction databases, was used for replication. …”
Get full text

Voacanga africana-artesunate and Voacanga africana-amodiaquine combinations as effective anti-plasmodial agents in mice by Daniel Ampomah Frimpong, Aliu Moomin, Samuel Asare Nkansah, Aaron Opoku Antwi, Abubakar Ibn Sidik, Paa Kofi Tawiah Adu-Gyamfi, Kwesi Boadu Mensah

“…However, the Plasmodium parasite frequently develops resistance to chemotherapy, triggering continuous research for effective treatment options for malaria. …”
Get full text

Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer by Jingmin Che, Bo Chen, Xusheng Wang, Baoe Liu, Cuixiang Xu, Huxia Wang, Jingying Sun, Qing Feng, Xiangrong Zhao, Zhangjun Song

“…In the absence of drug-targetable receptors, chemotherapy remains the sole systemic treatment alternative. …”
Get full text

Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study by Camille Windsor, Adrien Joseph, Stephanie Pons, Djamel Mokart, Frederic Pène, Achille Kouatchet, Alexandre Demoule, Fabrice Bruneel, Martine Nyunga, Edith Borcoman, Matthieu Legrand, Michael Darmon, Lara Zafrani, Elie Azoulay, Virginie Lemiale

“…Background: Cancer patients who are exposed to sepsis and had previous chemotherapy may have increased severity. Among chemotherapeutic agents, anthracyclines have been associated with cardiac toxicity. …”
Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

“…Accumulating evidence suggests rationales for continuing immunotherapy beyond progression, synergistic effects between immune checkpoint inhibitors and angiogenesis inhibitors, and a preferable combination of steroid-free chemotherapy with immunotherapy. These rationales imply that nanoparticle albumin-bound (nab)-paclitaxel plus ramucirumab in combination with nivolumab (anti-PD-1 antibody) may enhance anti-tumor effects as second-line treatment. …”
Get full text

Identification and validation of BATF as a prognostic biomarker and regulator of immune cell infiltration in acute myeloid leukemia by Zhe Zhao, Dongmei Wang, Dongmei Wang, Xue Sheng, Shuying Li, Tingting Liu, Mengyuan Chang, Lei Feng, Di Zhang, Chunyan Ji, Chunyan Ji, Fei Lu, Jingjing Ye

“…Moreover, the results showed that the expression level of BATF dramatically affected the effect of chemotherapy in AML patients. We also discovered that BATF expression could activate multiple immune-related pathways, altering the proportions of CD8+T cells and NK cells, suggesting that BATF may be a regulator of immune cell infiltration. …”
Get full text

Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study by Lana Jajac Brucic, Vesna Bisof, Majana Soce, Marko Skelin, Ivan Krecak, Andjela Nadinic, Branka Vrbicic, Zivana Puljiz, Suzana Hancic, Slavko Gasparov

“…Elevated expression of polo-like kinase 1 (PLK-1) has been linked to advanced disease stages and poorer treatment outcomes, including resistance to both chemotherapy and radiotherapy. However, data on PLK-1 expression in EOCRC compared to LOCRC remain limited. …”
Get full text

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study by Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD, Michelle S. Ginsberg, MD, Prasad S. Adusumilli, MD, FACS, Valerie W. Rusch, MD, Jennifer L. Sauter, MD, Teresa Ho, BS, Phillip Wong, PhD, Marjorie G. Zauderer, MD

“…We enrolled patients with progressive or recurrent DPM treated with at least one course of pemetrexed-based chemotherapy. Patients received two doses of GPS followed by six doses of GPS with intravenous nivolumab every 2 weeks, and up to six additional cycles until disease progression or unacceptable toxicity. …”
Get full text

MiR-3664-3p through suppressing ABCG2, CYP3A4, MCL1, and MLH1 increases the sensitivity of colorectal cancer cells to irinotecan by Elham Farrokhnazar, Sahar Moghbelinejad, Reza Najafipour, Ladan Teimoori-Toolabi

“…However, the 5-year survival rate for metastatic CRC remains below 10 %, largely due to chemotherapy resistance. Several genes, including ABCG2, CYP3A4, MCL1, and MLH1 contribute to irinotecan resistance. …”
Get full text

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives by Héverton Mendes Araújo, Gabriel Acácio de Moura, Yasmim Mendes Rocha, Cristian Vicson Pinheiro Gomes, Valentina Nascimento e Melo de Oliveira, Ronaldo Nascimento de Oliveira, Larissa Deadame de Figueiredo Nicolete, Emanuel Paula Magalhães, Ramon R.P.P.B. de Menezes, Roberto Nicolete

“…However, for more advanced cases with a high recurrence rate, the preferred approach is to combine chemotherapy with immunotherapy treatments. Tumor-associated macrophages (TAMs) are the most abundant leukocytes in solid tumors. …”
Get full text

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC by Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD

“…We also observe the aggressive nature of disease progression, frequent utilization of chemotherapy and antiangiogenic agents as initial subsequent therapies, and limited insight into resistance mechanisms due to infrequent rebiopsy and genomic profiling at progression.…”
Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

“…The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.Given the limited efficacy of pharmacological treatments, particularly for the recurrent disease, several molecularly targeted interventions have been explored, such as small-molecule protein kinase inhibitors (PKIs), inhibiting tyrosine kinase growth factor receptors and downstream signaling pathways involved in GBM angiogenesis and infiltrative behavior.This meta-analysis, based on searches in PubMed and Web Of Science, evaluated 12 randomized controlled trials (RCTs) examining PKIs in patients with newly diagnosed or recurrent GBM. …”
Get full text

IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity by Haoyu Ji, Wenya Ma, Xu Liu, Hongyang Chen, Yining Liu, Zhongyu Ren, Daohong Yin, Ao Cai, Zizhen Zhang, Xin Wang, Wei Huang, Leping Shi, Yanan Tian, Yang Yu, Xiuxiu Wang, Yang Li, Yu Liu, Benzhi Cai

“…Abstract Doxorubicin (DOX) is a first-line chemotherapy agent known for its cardiac toxicity. DOX-induced cardiotoxicity (DIC) severely limits the use for treating malignant tumors and is associated with a poor prognosis. …”
Get full text

plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute... by Thomas R Fanshawe, Philip J Turner, Gail N Hayward, Margaret Glogowska, Alastair D Hay, Michael Moore, Mark Lown, Christopher C Butler, Mandy Wootton, Mark H Wilcox, Jane Freeman, Nicola Kenealy, Valerie Tate, Owain Llion, Rebecca Lowe

Get full text

Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil by Pamela Santos Azevedo, Isabella Zuppo Laper, Deborah Marta do Santos Oliveira, Adriano de Paula Sabino, Marina Morgado Garcia, Isabela Cristina Menezes de Freitas, Isabela Cristina Menezes de Freitas, Wallace Mateus Prata, Wallace Mateus Prata, Mariângela Leal Cherchiglia, Juliana Álvares-Teodoro, Juliana Álvares-Teodoro, Francisco de Assis Acurcio, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior, Augusto Afonso Guerra Júnior

“…There are few studies on FL in Brazil, so this study aims to evaluate the patient’s profile, morbidity and mortality treated by the Brazilian national health service (SUS) and evaluate risk factors associated with treatment failure.MethodsThis is a nationwide 16 years cohort with patients that underwent chemotherapy in the SUS (2000–2015). The Kaplan-Meier method was used to estimate survival until treatment failure, and the Cox proportional hazards model was used to evaluate risk factors.ResultsThe cohort included 10,009 patients and survival rates were 73.3%, 45.3%, and 30.7% for the first, fifth and 10th year respectively. …”
Get full text

Oncolytic influenza virus enhances killing effect of gemcitabine against pancreatic cancer cells by MENG Zihe, MENG Zihe, XU Yongru, DENG Zhaoda

“…Objective‍　‍To investigate the killing effect of the recombinant oncolytic influenza virus OvFlu-GM-CSF， constructed using reverse genetics （RG） technology， in combination with chemotherapy drug， gemcitabine （GEM）， against pancreatic cancer cells. …”
Get full text

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301) by Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Azusa Komori, Kazuo Nishikawa, Satoshi Otsu, Ayumu Hosokawa, Hisanobu Oda, Tatsunori Sakai, Shuji Arita, Machiko Kawahira, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…The primary endpoint is disease‐free survival in patients who have undergone radical therapy (surgery and radiotherapy) or progression‐free survival in those receiving targeted therapy (first, second, and subsequent lines), chemotherapy (first and subsequent lines), combination therapy, and palliative/maintenance therapy according to stages of EGFR‐mutated NSCLC. …”
Get full text

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial by Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, Zoé Tharin, Leila Bengrine, Hélène Bellio, Aurélie Bertaut, Léa Hampe, Susy Daumoine, Emilie Rederstorff, Morgane Peroz, Titouan Huppe, Valentin Derangère, David Rageot, John Simard, Caroline Truntzer, Jean David Fumet, Francois Ghiringhelli

“…The combination of XB2001 with FTD/TPI and bevacizumab is feasible and safe, and showed encouraging clinical activity in chemotherapy-resistant mCRC.…”
Get full text

Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors by Keng Lam, MD, Lewis F. Nasr, MD, Clark R. Andersen, MS, Kathryn E. Marqueen, MD, Jing Li, MD, PhD, Chenyang Wang, MD, Thomas H. Beckham, MD, PhD, Nazanin K. Majd, MD, PhD, Ashley E. Aaroe, MD, Monica Loghin, MD, Barbara J. O'Brien, MD, Susan L. McGovern, MD, PhD

“…Following pCSI, 4% received intrathecal chemotherapy, 67% systemic therapy, and 9% hospice care; 18% were observed and 2% lost to follow-up. …”
Get full text